Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day